Lysosomal Alpha Glucosidase - Pipeline Review, H2 2017, outlays comprehensive information on the Lysosomal Alpha Glucosidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 188.8.131.52) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 7 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders which include indications Pompe Disease.
Complete Report Available at www.themarketreports.com/report/ly…e-review-h2-2017
- The report provides a snapshot of the global therapeutic landscape for Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 184.108.40.206)
- The report reviews Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 220.127.116.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
Access this Report at www.themarketreports.com/report/941452
Reasons To Access
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 18.104.22.168)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
Inquire About this Report at www.themarketreports.com/report/ask-your-query/941452
Category: Market Research Publishers and RetailersCompany about: The Market Reports aims to provide the best industry and market reports to a seeker. We are looking forward to a place where we are the one stop destination for all the report seekers irrespective of any country, category, domain, etc. We are always open on call and email (24*7) to your queries and very clean with the business methodology. Since we are dealing with so many Publishers, we can actually give you what suits best in accordance to your requirements.
For more information: